Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Up 6.52%
As of Monday, July 27, Compass Therapeutics, Inc.’s CMPX share price has surged by 6.52%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Down 5.16%
As of Friday, July 10, Compass Therapeutics, Inc.’s CMPX share price has dipped by 5.16%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Up 5.58%
As of Wednesday, June 17, Compass Therapeutics, Inc.’s CMPX share price has surged by 5.58%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Up 8.18%
As of Wednesday, May 27, Compass Therapeutics, Inc.’s CMPX share price has surged by 8.18%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Compass Therapeutics, Inc.’s (CMPX) Stock Is Up 5.70%
As of Friday, May 22, Compass Therapeutics, Inc.’s CMPX share price has surged by 5.70%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | CMPX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $344.0 | $252.6 | 33% |
|
| Shares Out (Mil) | 186.4 | 52.3 | 75% |
|
| Institutional Ownership | 92.7% | 92.1% | 62% |
|
| Float (Mil) | 122.7 | 40.2 | 65% |
|
| Beta | 0.67 | 0.95 | 39% |
|
| Avg Daily Volume (000s) | 2,343 | 455 | 84% |
|
| Price Change (52-week) |
(37.4%) | 52.9% | 21% |
|
| Growth | CMPX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (17.7%) | (9.9%) | 22% |
|
| EPS (5yr) | 15.1% | 16.0% | 56 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (16.1%) | (15.6%) | 45% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 12 | |
| Current EPS | ($0.108) | ($0.434) | ($0.463) | |
| Month Ago EPS | ($0.109) | ($0.436) | ($0.463) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.100) | ($0.427) | ($0.407) | |
| Year/Year Chg | 10.2% | 2.8% | (59.7%) | |
| Financials | CMPX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($68) | ($43) | 14% |
|
| EPS (TTM) | ($0.402) | ($1.600) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($53) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $14 | $5 | 60% |
|
| Long-Term Debt (Q1) (Mil) | $8 | $5 | 27% |
|
| Enterprise Value (Q1) (Mil) | $152 | $180 | 24% |
|
| Valuation | CMPX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.84 | 2.56 | 48% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CMPX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (40.5%) | (49.8%) | 14% |
|
| ROE | (45.9%) | (55.5%) | 16% |
|
| Liabilities to Assets | 9.1% | 30.3% | 5% |
|
| F-Score | 2 | 3 | 7% |
|
Compass Therapeutics, Inc. did not pass any screens on 7/31/2026.
